Navigation Links
Telik Announces New TRAP Drug Discovery Agreement
Date:11/12/2008

olecules and to optimize these structures into new drug candidates.

About Telik

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.

Forward Looking Statements

This press release contains "forward-looking" statements, including statements regarding the potential application and capabilities of TRAP, and the potential utility of TRAP to HSS' drug discovery efforts. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended September 30, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Telik Announces Financial Results for 2008 Third Quarter
2. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
3. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
4. Telik Announces Receipt of Nasdaq Notice
5. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
6. ReceptorBio Announces Diabetes License Agreement With Telik
7. Telik Announces Financial Results For 2008 Second Quarter
8. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
9. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
10. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
11. Telik Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Sensitive detection method may help impede illicit nuclear trafficking 2
... Ltd. has found that the,Replikin Count(TM) of the H1N1 ... 1.4), its highest level since the 1918 H1N1,pandemic (p ... a particular,influenza strain, indicating rapid replication of the virus, ... an outbreak of the specific,strain. The current increase appears ...
... Kantor joins founding management team to direct ITI,s Center for ... Critical ... Immune Tolerance,Institute Inc., (ITI) today announced that Aaron B. Kantor, Ph.D. ... Louis A. Matis, M.D., President and Chief Executive Officer. Prior to,joining ...
... April 7, 2008 Ardea Biosciences,Inc. (Nasdaq: ... presented on its,second generation non-nucleoside reverse transcriptase inhibitors ... (ICAR).,Additionally, data on two of the Company,s mitogen-activated ... presented at the American,Association for Cancer Research (AACR) ...
Cached Biology Technology:H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria 2Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 2Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 3Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer 4Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 2Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 3
(Date:7/10/2014)... , July 3, 2014 According ... by Type (Swipe And Area), Material (Optical Prism, Pizeoelectric, ... Commercial Security and Banking & Finance), and Geography - ... by MarketsandMarkets, the global Fingerprint Sensors Market is projected ... high CAGR of 16.8% from 2014 to 2020. ...
(Date:7/10/2014)... July 7, 2014 Fingerprint Cards, (FPC,s) ... design win (DW). A Chinese Top 5 smartphone OEM has ... of mass production in October 2014.   FPC ... 5 smartphone OEM, which has a planned date for the ... sales volume for this phone of 3 million units. The ...
(Date:7/10/2014)... GOTHENBURG, Sweden , July 8, 2014 ... FPC1021 has won a new design win (DW). An Asian ... targeted date for mass production start in August 2014.   ... an Asian smartphone OEM, which has a planned date for ... received an initial ramp order of SEK 5M, for delivery ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... one key reason why blood stem cells are susceptible to ... Their finding also may explain, they say, why some other ... Cell Stem Cell " (Aug. 6, 2010) and reviewed in ... a new frontier for studying the molecular underpinnings of adult ...
... (August 16, 2010, 9:00 a.m. EDT) A ... promotes angiogenesis, the growth of new blood vessels. ... significantly reduced angiogenesis in mice. These discoveries, published ... Experimental Medicine , may lead to novel treatments ...
... HOUSTON -- (Aug. 16, 2010) -- A new ... and other human activity has completely obscured the natural ... "The natural factors that influence carbon dioxide cycling ... the radiocarbon signature of the river to reflect those ...
Cached Biology News:Blood stem cell, leukemia link illuminated in UCSF-led study 2Blood stem cell, leukemia link illuminated in UCSF-led study 3Scientists reveal new targets for anti-angiogenesis drugs 2A river flipped: Humans trump nature on Texas river 2A river flipped: Humans trump nature on Texas river 3
... to Ki67 - Proliferation Marker, prediluted ... related nuclear protein, expressed by proliferating cells ... cycle (G1, S, G2 and M phase). ... Ki67 antibodies are useful in establishing the ...
Request Info...
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
Biology Products: